Every Form 4 that Myomo Inc. (MYO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MYO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYO filings page.
MYOMO, INC. (MYO) reported that Chief Medical Officer Harry Kovelman sold 15,488 shares of common stock on September 11, 2026 in an open-market or private transaction at a weighted-average price of $1.2709 per share, with individual trade prices ranging from $1.25 to $1.29 per share.
After this sale, he directly holds 90,245 shares of MYOMO common stock. No transactions in this filing are reported as made under a Rule 10b5-1 trading plan.
MYOMO, INC. (MYO) director Morris Milton Mayo reported selling 15,000 shares of Common Stock on September 2, 2026 in a single lot at $1.41 per share in an open market or private transaction. Following this sale, he directly holds 208,391 shares of MYO common stock. No Rule 10b5-1 trading plan is reported.
MYOMO, INC. (MYO) reports an amended insider transaction for Chief Medical Officer Harry Kovelman. On August 20, 2026, he executed an open-market sale of 17,500 shares of common stock at a weighted average price of $1.7331 per share, with individual trade prices ranging from $1.72 to $1.75. Following this transaction, he beneficially owned 105,733 shares of MYO common stock. The amendment corrects the originally reported shares sold and resulting holdings; no other aspects of the prior filing were changed.
MYOMO, INC. (MYO) reported that Chief Medical Officer Harry Kovelman sold common stock in an open-market transaction. On 2026-08-20, he sold 17,250 shares at a weighted average price of $1.7331 per share, with individual sale prices ranging from $1.72 to $1.75. Following this sale, he directly holds 105,983 shares of MYO common stock. The transaction was not reported as being made under a Rule 10b5-1 trading plan.
MYOMO, INC.'s Chief Medical Officer, Harry Kovelman, reported equity compensation activity involving common stock. On August 7, 2026, he received a grant of 55,149 fully vested Restricted Stock Units as payment for incentive compensation earned for the fiscal year ended December 31, 2025. On the same date, 22,457 shares were disposed of and withheld solely to pay income and other taxes associated with the vesting of these RSUs.
Myomo, Inc. reported that Chief Commercial Officer Micah Mitchell received a grant of 58,409 shares of Common Stock on August 7, 2026 as fully vested Restricted Stock Units paid as incentive compensation for the fiscal year ended December 31, 2025. On the same date, 21,559 shares were withheld and disposed of at $1.42 per share to pay related income and other taxes.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis received an equity compensation award. On August 7, 2026, he acquired 146,909 shares of common stock through a grant of fully vested Restricted Stock Units as payment for incentive compensation earned for the fiscal year ended December 31, 2025. Following this award, he holds 1,434,679 shares of common stock directly.
MYOMO, INC. Chief Financial Officer David A. Henry reported equity compensation activity on August 7, 2026. He received a grant of 68,644 shares of Common Stock via fully vested Restricted Stock Units as incentive compensation for the fiscal year ended December 31, 2025. On the same date, 25,310 shares of Common Stock were withheld at $1.42 per share to pay associated income and other taxes related to this RSU vesting.
Myomo, Inc. Chief Financial Officer David A. Henry reported compensation-related equity transactions in Myomo common stock. On July 10, 2026, he received a grant of 7,840 Restricted Stock Units under a Board-approved program allowing employees to exchange 10% of salary for RSUs, with a grant date fair value of 115% of the salary exchanged; this grant covers three months of salary and vests in full on October 10, 2026. On July 13, 2026, 5,166 shares were disposed of solely to cover income taxes from RSU vesting, pursuant to an irrevocable election made on December 11, 2025. Following these transactions, Henry holds 426,829 shares of Myomo common stock directly.
GUDONIS PAUL R reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. Chief Executive Officer Paul R. Gudonis received a grant of 10,454 Restricted Stock Units as equity compensation. The grant is part of a program allowing employees to exchange 10% of salary for RSUs with a grant date fair value of 115% of the salary exchanged, covering three months of salary. These RSUs vest in full on October 10, 2026. Following this grant, Gudonis directly holds 1,287,770 shares of common stock.
MYOMO, INC. director Joseph M. Manko Jr. reported an acquisition of 78,704 shares of Common Stock as a grant or award. The transaction was recorded at a price of $0.00 per share, and his direct holdings after the transaction total 78,704 shares.
A footnote states he elected to defer receipt of the common stock issuable upon vesting of the related RSUs until the earlier of 30 days after termination of service or a change in control.
Crowley Thomas Aloysius Jr. reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Thomas Aloysius Crowley Jr. received a grant of 78,704 Restricted Stock Units, each representing one share of common stock, at no cash cost. These RSUs vest in four equal quarterly installments beginning on September 9, 2026. Following this award, he directly holds 154,452 shares.
KIRK THOMAS F reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Kirk Thomas F reported receiving a grant of 78,704 Restricted Stock Units under the company’s 2018 Stock Option and Incentive Plan. Each unit represents a contingent right to one share of common stock.
The Restricted Stock Units vest in four equal quarterly installments beginning on September 9, 2026, meaning the director earns the shares over time rather than all at once. Following this grant, he reports beneficial ownership of 772,569 shares or units of common stock.
Getz Heather C reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Heather C. Getz reported a grant of 78,704 shares of Common Stock in the form of Restricted Stock Units under the company’s 2018 Stock Option and Incentive Plan. This was a compensation award, not an open-market purchase.
Each RSU represents a contingent right to receive one share of common stock and will vest in four quarterly installments beginning on September 9, 2026. Getz has elected to defer receipt of the underlying common shares until the earlier of 30 days after her service ends or a change in control. Following this grant, she directly holds 210,458 shares of common stock.
FEBBO WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director William J. Febbo reported an equity compensation grant of 78,704 shares of Common Stock in the form of Restricted Stock Units under the company’s 2018 Stock Option and Incentive Plan. The RSUs carry no cash purchase price and represent a contingent right to receive one share of common stock each.
The RSUs vest in four equal quarterly installments beginning on September 9, 2026. After this grant, Febbo directly holds a reported total of 123,704 shares of MYOMO common stock.
Morris Milton Mayo reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Morris Milton Mayo reported an award of 78,704 shares of common stock in the form of Restricted Stock Units under the company’s 2018 Stock Option and Incentive Plan. Following the grant, he directly holds 223,391 shares.
The RSUs vest in four equal quarterly installments beginning on September 9, 2026, with each unit representing a contingent right to receive one share of common stock. Mayo has elected to defer actual receipt of the common stock until the earlier of 30 days after his service ends or a change in control.
MYOMO, INC. Chief Medical Officer Harry Kovelman reported a Form 4 transaction where 10,442 shares of Common Stock were sold at $1.20 per share on June 12, 2026. According to the footnote, these shares were sold solely to pay income taxes from restricted stock units that vested on June 11, 2026, under an earlier irrevocable election. After this tax-withholding disposition, Kovelman directly owns 90,541 shares.
MYOMO, INC. Chief Commercial Officer Micah Mitchell reported a tax-related share disposition. On June 12, 2026, 9,061 shares of common stock at $1.20 per share were delivered to cover income taxes arising from restricted stock units that vested on June 11, 2026, under a prior irrevocable election. Following this transaction, he holds 93,888 shares of common stock directly.
MYOMO, INC. Chief Financial Officer David A. Henry reported a routine tax-related share disposition. On June 12, 2026, 10,969 shares of common stock were withheld to cover income taxes arising from restricted stock units that vested on June 11, 2026. This was an automatic tax-withholding event, not an open-market sale. After the withholding, Henry directly holds 424,155 shares of Myomo common stock.
MYOMO, INC. Chief Commercial Officer Micah Mitchell reported a compensation-related share disposition. On the vesting of restricted stock units, 6,529 shares of common stock were delivered on June 8, 2026 solely to cover income taxes at $1.33 per share. After this tax-withholding event, Mitchell directly holds 102,949 MYO shares.
MYOMO, INC. Chief Medical Officer Harry Kovelman reported a routine tax-related share disposition. On June 8, 2026, 7,635 shares of common stock were sold at $1.33 per share solely to cover income taxes from restricted stock units that vested on June 5, 2026. After this transaction, he directly holds 100,983 shares.
MYOMO, INC. Chief Financial Officer David A. Henry had 10,050 shares of common stock withheld on June 8, 2026 to cover income taxes from restricted stock units that vested on June 5, 2026. After this tax-withholding disposition, he directly holds 435,124 shares of MYO common stock.
MYOMO, INC. director F. Kirk Thomas reported an open-market purchase of 40,002 shares of common stock on June 5, 2026 at a weighted average price of $1.27 per share. The filing notes the shares were bought in multiple lots at prices ranging from $1.23 to $1.30 per share. Following this transaction, Thomas directly owns 693,865 shares of Myomo common stock.
MYOMO, INC. Chief Commercial Officer Micah Mitchell sold 90,231 shares of common stock in open-market transactions on May 14, 2026. The weighted average sale price was $0.861 per share, with individual lots ranging from $0.85 to $0.889 per share. After these sales, Mitchell directly holds 109,478 shares of MYOMO common stock.
MYOMO, INC. director F. Kirk reported an open-market purchase of 25,000 shares of Common Stock on May 28, 2026 at $0.993 per share. The shares were bought in multiple lots at this price. Following the transaction, his direct holdings increased to 653,863 shares.
MYOMO, INC. Chief Medical Officer Harry Kovelman reported open-market sales of company common stock over two days. He sold 20,464 shares on May 27, 2026 at a weighted average price of $1.002 per share and 11,536 shares on May 28, 2026 at a weighted average price of $1.0172 per share. After these transactions, he continued to hold 108,618 shares directly.
MYOMO, INC. director F. Thomas Kirk reported two open-market purchases of common stock. On May 15, 2026, he bought 31,605 shares at a weighted average price of $0.9096 per share, in multiple lots priced between $0.815 and $0.91.
On May 18, 2026, he bought an additional 43,401 shares at a weighted average price of $0.91 per share, with individual trades between $0.9041 and $0.91. After these purchases, he directly owns 628,863 common shares.
MYOMO, INC. director Joseph M. Manko Jr., through Horton Capital Partners Fund, LP, reported net open-market purchases of 201,197 MYO shares. The fund bought 170,830 shares at an average price of $0.8602 per share on May 14, 2026, and 30,367 shares at $0.8878 per share on May 15, 2026. Following these indirect transactions, the fund’s reported MYO holdings rose to 2,309,775 shares.
MYOMO, INC. Chief Commercial Officer Micah Mitchell reported an open-market sale of 90,231 shares of common stock on May 14. The weighted average sale price was $0.861 per share, with individual trades executed between $0.85 and $0.889 per share. After these transactions, Mitchell directly owns 109,478 shares of Myomo common stock.
FEBBO WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director William J. Febbo received an equity award covering 45,000 shares of Common Stock as compensation. The Form 4 shows this as a grant of restricted stock units under the company’s 2018 Stock Option and Incentive Plan, with no cash paid per share.
The RSUs vest in full on the first anniversary of the grant date, meaning the entire 45,000-unit award is scheduled to vest after one year if conditions are met. Following this award, Febbo reports beneficial ownership of 45,000 shares/units directly, reflecting a routine, compensation-related equity grant rather than an open‑market purchase or sale.
GUDONIS PAUL R reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis received a grant of 16,666 shares of Common Stock in the form of Restricted Stock Units (RSUs). This award comes under a program allowing employees to forego 10% of their salary for three months in exchange for RSUs with a grant date fair value equal to 115% of the salary exchanged. The RSUs vest in full on July 9, 2026. After this grant, Gudonis directly holds 1,277,316 shares of the company’s common stock.
MYOMO, INC. Chief Financial Officer David A. Henry reported routine equity compensation and related tax withholding transactions in company stock. He received 12,500 Restricted Stock Units under a board-approved program where employees exchange 10% of three months of salary for RSUs valued at 115% of the salary given up. These RSUs vest in full on July 9, 2026. On April 13, 2026, 3,953 shares of common stock at $0.71 per share were disposed of solely to pay income taxes on restricted stock units that vested on April 12, 2026, pursuant to an irrevocable election made on December 11, 2025. Following these transactions, he directly holds 445,174 shares of Myomo common stock.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis acquired 19,395 shares of common stock through a grant of Restricted Stock Units (RSUs) with no cash paid per share. These RSUs were issued under a program allowing employees to exchange 10% of their salary for equity at a grant date fair value of 115% of the salary given up, covering three months of salary.
The RSUs from this grant vest in full on July 9, 2026. After this award, Gudonis directly holds a total of 1,280,045 shares of Myomo common stock, underscoring that this is primarily a compensation-related equity grant rather than an open‑market purchase.
MYOMO, INC. director Heather C Getz reported an open-market purchase of company stock. On March 16, 2026, she bought 20,000 shares of Myomo common stock at $0.6986 per share, in a single open-market transaction. Following this trade, her direct ownership increased to 131,754 shares of common stock.
MYOMO, INC. director Kirk Thomas F reported an open-market purchase of 72,000 shares of Common Stock. The weighted average purchase price was about $0.7099 per share, with individual trade prices ranging from $0.70 to $0.71. Following these purchases, he directly owns 553,857 shares.
MYOMO, INC. director Heather C. Getz made an open-market purchase of 70,000 shares of common stock at a weighted average price of $0.728 per share. The trades were executed in multiple lots between $0.72 and $0.73 per share.
Following this transaction, she directly owns 111,754 shares of MYOMO common stock. The filing describes these transactions as open-market purchases, indicating she used personal capital to increase her direct equity position in the company.
Myomo, Inc. reported that Chief Executive Officer and director Paul R. Gudonis received a grant of 11,637 shares of common stock on January 12, 2026 at a price of $0 per share. After this grant, he beneficially owned 1,260,650 shares of Myomo common stock in direct form.
The shares represent Restricted Stock Units under a Board-approved program that allows employees to forego 10% of their salary in exchange for RSUs with a grant date fair value of 115% of the salary exchanged. This particular grant covers three months of salary, and the RSUs vest in full on April 12, 2026.
Myomo, Inc. reported a new equity award to its Chief Financial Officer, David A. Henry. On January 12, 2026, he acquired 8,727 shares of common stock at a stated price of $0 per share, increasing his total beneficial ownership to 436,627 shares held directly.
According to the footnote, the award represents Restricted Stock Units granted under a Board-approved program that allows employees to forego 10% of their salary in exchange for RSUs with a grant date fair value of 115% of the salary exchanged. This particular grant covers three months of salary and the RSUs vest in full on April 12, 2026.
Myomo, Inc. (MYO) reported insider share purchases by a director. On 11/20/2025, the director bought 4,902 shares of common stock in the open market at $0.72 per share, and on 11/21/2025 bought an additional 2,535 shares at $0.72 per share. After these transactions, the director beneficially owned 481,857 shares of Myomo common stock in direct ownership. The purchases were disclosed on a Form 4 filed for a single reporting person.
Myomo, Inc. director reports open-market share purchases on a Form 4. The reporting person bought 4,000 shares of Myomo common stock on 11/18/2025 at a price of $0.7345 per share in a single open-market transaction. On 11/19/2025, an additional 385 shares were purchased at a weighted average price of $0.765 per share. Following these transactions, the reporting person beneficially owned 75,748 shares directly and 479 shares indirectly through an immediate family member, for which beneficial ownership is disclaimed except to the extent of any pecuniary interest.